SCM
ACOR

Scopia Capital Management’s Acorda Therapeutics ACOR Stock Holding History

Scopia Capital Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-23,115
Closed -$7.96M – 26
2019
Q3 		$7.96M Sell
23,115
-4,580
-17% -$2.49M 0.47% 19
2019
Q2 		$25.5M Sell
27,695
-9,472
-25% -$11.6M 1.13% 20
2019
Q1 		$59.3M Sell
37,167
-8,592
-19% -$15.5M 2.19% 16
2018
Q4 		$85.5M Sell
45,759
-13,466
-23% -$29.3M 2.9% 15
2018
Q3 		$140M Sell
59,225
-4,413
-7% -$13.7M 2.69% 15
2018
Q2 		$219M Sell
63,638
-6,985
-10% -$21.4M 3.83% 9
2018
Q1 		$200M Hold
70,623
– – 4.01% 9
2017
Q4 		$182M Hold
70,623
– – 3.26% 11
2017
Q3 		$200M Buy
70,623
+10,424
+17% +$27.5M 3.17% 12
2017
Q2 		$142M Buy
60,199
+13,796
+30% +$27.3M 2.94% 12
2017
Q1 		$117M Buy
46,403
+8,636
+23% +$24.9M 2.16% 18
2016
Q4 		$85.2M Buy
37,767
+2,734
+8% +$6.5M 1.61% 21
2016
Q3 		$87.8M Buy
35,033
+8,606
+33% +$25.7M 1.55% 22
2016
Q2 		$80.9M Buy
26,427
+4,298
+19% +$14M 1.67% 22
2016
Q1 		$70.2M Buy
22,129
+5,850
+36% +$24.3M 1.31% 24
2015
Q4 		$83.6M Buy
16,279
+11,552
+244% +$50.5M 1.66% 21
2015
Q3 		$15M Buy
+4,727
New +$18.3M 0.32% 32

Other funds holding ACOR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Scopia Capital Management's ACOR Position: Q4 2019 in Review

Scopia Capital Management sold out of Acorda Therapeutics (ACOR) in Q4 2019, closing a stake of 23,115 shares — an estimated $7.96M sold.

Scopia Capital Management first reported a position in ACOR in Q3 2015 and held it in 17 quarters. The position peaked at $219M in Q2 2018. 121 funds tracked by Wall St. Rank hold ACOR as of Q4 2019.

  • Scopia Capital Management reported no remaining Acorda Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Scopia Capital Management sold 23,115 Acorda Therapeutics shares in Q4 2019, an estimated $7.96M.
  • Scopia Capital Management first reported a position in Acorda Therapeutics in Q3 2015 and held it in 17 quarters.
  • Scopia Capital Management's Acorda Therapeutics position peaked at $219M in Q2 2018.
  • 121 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2019.

Based on Scopia Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.